Regression of Intermediate-High Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) With Long-term Use of Curcumin: A Case Report
Sign Up to like & getrecommendations! Published in 2024 at "Integrative Cancer Therapies"
DOI: 10.1177/15347354241242099
Abstract: Patients with intermediate-high risk MGUS are not offered therapeutic options to date and standard of care remains observation with re-evaluations of the patient every 3 to 6 months. Given the persistent risk of progression as well… read more here.
Keywords: regression intermediate; risk monoclonal; mgus; intermediate high ... See more keywords